XML 125 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Operations - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Statement [Abstract]                      
Net sales $ 1,353 $ 1,390 $ 1,408 $ 1,376 $ 1,464 $ 1,628 $ 1,816 $ 1,730 $ 5,526 $ 6,638 $ 6,183
Cost of goods sold 1,203 1,096 1,085 1,080 1,064 1,151 1,259 1,193 4,463 4,667 4,438
Gross profit                 1,063 1,971 1,745
Selling, general, and administrative expense                 548 657 626
Research and development expense                 80 82 81
Restructuring, asset-related, and other charges                 87 49 57
Total other operating expenses                 715 788 764
Equity in earnings of affiliates                 29 43 33
Interest expense, net                 (208) (195) (214)
Loss on extinguishment of debt                 0 (38) (1)
Other (expense) income, net                 (293) 162 113
(Loss) income before income taxes (454) 91 133 107 182 269 323 381 (124) 1,155 912
(Benefit from) provision for income taxes                 (72) 159 165
Net (loss) income (317) 76 96 94 142 275 282 297 (52) 996 747
Less: Net income attributable to non-controlling interests                 0 1 1
Net (loss) income attributable to Chemours $ (317) $ 76 $ 96 $ 94 $ 142 $ 275 $ 281 $ 297 $ (52) $ 995 $ 746
Per share data                      
Basic (loss) earnings per share of common stock $ (1.94) $ 0.46 $ 0.58 $ 0.56 $ 0.83 $ 1.56 $ 1.58 $ 1.63 $ (0.32) $ 5.62 $ 4.04
Diluted (loss) earnings per share of common stock $ (1.94) $ 0.46 $ 0.57 $ 0.55 $ 0.81 $ 1.51 $ 1.53 $ 1.58 $ (0.32) $ 5.45 $ 3.91